Business Context and Reporting Period
This Form 8-K is filed by Histogenics Corporation (the "Company") on April 18, 2019, reporting events occurring on April 16, 2019. The filing addresses the Company's failure to meet Nasdaq listing requirements and the status of a proposed merger with Ocugen, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate governance, listing status, and merger terms rather than financial performance data.
Material Changes and Events
- Nasdaq Delisting Notice: On April 16, 2019, Histogenics received notification from Nasdaq that its common stock would be delisted due to continued non-compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)). The Company was not eligible for a second grace period because it failed to meet the stockholders' equity initial listing requirement.
- Merger Agreement: On April 5, 2019, Histogenics entered into a Merger Agreement with Ocugen, Inc. Under the terms, Ocugen will merge into a Histogenics subsidiary, with Ocugen surviving as a wholly-owned subsidiary of Histogenics.
- Ownership Structure: Upon closing, former Ocugen equity holders are expected to own approximately 90% of the combined company, while Histogenics stockholders will own approximately 10%. This ratio is subject to adjustments based on cash at closing and unconverted convertible notes.
Guidance, Outlook, and Risks
Outlook and Next Steps: Histogenics plans to request a hearing before a Nasdaq Hearings Panel, expected in the second quarter of 2019, to contest the delisting. The Company expects its stock to continue trading on Nasdaq under the symbol "HSGX" until a decision is issued. If delisted, trading is expected to move to the over-the-counter market. The Merger Agreement contemplates that the combined company will continue to be listed on Nasdaq, though there is no assurance this will occur.
Risks and Contingencies:
- There is no assurance the Nasdaq Hearings Panel will grant continued listing.
- The Merger is subject to customary closing conditions, including stockholder approval from both companies.
- Forward-looking statements regarding the merger structure, timing, and the combined company's operations involve significant risks, including potential failure to obtain regulatory approvals, delays in clinical trials for Ocugen's product candidates, and insufficient capital to advance development.
- Ownership percentages may vary based on adjustments to the exchange ratio formula.
Investor Verification Checklist
- Verify the outcome of the Nasdaq Hearings Panel regarding Histogenics' delisting.
- Confirm the final exchange ratio and ownership split between Histogenics and Ocugen stockholders upon closing.
- Review the upcoming Form S-4 registration statement and proxy materials for detailed merger terms and risk factors.
- Monitor the status of stockholder approvals required for the Merger Agreement.
- Assess the combined company's ability to meet Nasdaq initial listing requirements post-merger.